On the Record · Lakefront Biotherapeutics
Lakefront Biotherapeutics acquisitions, on the record
The businesses Lakefront Biotherapeutics bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
CellPoint B.V.Word for word“On June 21, 2022, we acquired all outstanding shares of CellPoint B.V., a Dutch company dedicated to developing CAR-T therapies at the point-of-care, and AboundBio, Inc., a privately held U.S. biotechnology company.” 20-F for 2023 | acquisition | June 21, 2022 | — |
AboundBio, Inc.Word for word“AboundBio was acquired for a payment of $14 million.” 20-F for 2023 | acquisition | — | $14 million |
FideltaWord for word“On January 4, 2021 however we sold our Croatian subsidiary and fee for service business Fidelta to Selvita, who acquired 100% of the outstanding shares in Fidelta.” 20-F for 2023 | divestiture | January 4, 2021 | — |
Jyseleca® businessWord for word“On October 30, 2023, we signed a letter of intent contemplating a transfer of the Jyseleca® business to Alfasigma S.p.A.” 20-F for 2023 | agreed divestiture | October 30, 2023 | — |
NovAliX drug discovery collaborationWord for word“We completed the integrated drug discovery collaboration transaction with NovAliX on June 30, 2023, effective as from July 1, 2023.” 20-F for 2023 | agreed acquisition | June 30, 2023 | — |
CellPoint B.V. (CellPoint)Word for word“CellPoint was acquired for an upfront payment of €125 million, with milestone payments of up to €100 million.” 20-F for 2024 | acquisition | — | an upfront payment of €125 million, with milestone payments of up to €100 million |
AboundBio, Inc. (AboundBio)Word for word“AboundBio was acquired for a payment of $14 million.” 20-F for 2024 | acquisition | — | a payment of $14 million |
Jyseleca® business to Alfasigma S.p.A. (Alfasigma)Word for word“On October 30, 2023, we signed a letter of intent contemplating a transfer of the Jyseleca® business to Alfasigma S.p.A., or Alfasigma.” 20-F for 2024 | agreed divestiture | October 30, 2023 | — |
Jyseleca® business to AlfasigmaWord for word“The sale of the Jyseleca® business to Alfasigma on January 31, 2024 led to the full recognition in revenue in 2024 of the remaining deferred income related to filgotinib.” 20-F for 2024 | divestiture | January 31, 2024 | — |
Galapagos Real Estate Belgium BVWord for word“In December 2024, we signed a share purchase agreement regarding the shares of Galapagos Real Estate Belgium BV.” 20-F for 2024 | agreed divestiture | — | — |
Read from Lakefront Biotherapeutics’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-03-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.